{"id":63908,"date":"2026-04-24T20:56:31","date_gmt":"2026-04-24T12:56:31","guid":{"rendered":"https:\/\/flcube.com\/?p=63908"},"modified":"2026-04-24T20:56:32","modified_gmt":"2026-04-24T12:56:32","slug":"regeneron-secures-fda-approval-for-otarmeni-gene-therapy-and-announces-landmark-u-s-pricing-agreement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63908","title":{"rendered":"Regeneron Secures FDA Approval for Otarmeni Gene Therapy and Announces Landmark U.S. Pricing Agreement"},"content":{"rendered":"\n

Regeneron Pharmaceuticals Inc.<\/strong> (NASDAQ: REGN<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has granted an additional indication authorization for Otarmeni (lunsotogene parvec-cwha)<\/strong>, making it the first approved gene therapy<\/strong> and second new molecular entity under the FDA Commissioner’s National Priority Voucher program<\/strong>. On the same day, Regeneron revealed a landmark agreement with the U.S. government to provide the therapy free of charge while implementing broader drug pricing reforms.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Therapy<\/strong><\/td>Otarmeni (lunsotogene parvec-cwha)<\/td><\/tr>
Technology<\/strong><\/td>Adeno-associated virus (AAV) vector-based gene therapy<\/td><\/tr>
FDA Program<\/strong><\/td>National Priority Voucher program<\/td><\/tr>
Significance<\/strong><\/td>First approved gene therapy under this program<\/td><\/tr>
Previous Designation<\/strong><\/td>Formerly known as DB-OTO<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Therapeutic Profile & Mechanism<\/h2>\n\n\n\n